Division of Nucleic Acid Therapy
Development of Personalized Tumor Neoantigen mRNA Vaccines
Cancer neoantigen vaccines are emerging as a promising new approach in precision cancer immunotherapy, but major challenges remain in identifying the best targets, improving vaccine efficacy, and advancing personalized therapies toward clinical use. The mission of our division is to address these challenges through the development of next-generation personalized mRNA-LNP cancer vaccines.
Our work focuses on improving the discovery and prioritization of tumor neoantigens through an in-house workflow that integrates tumor genomic information with computational and immunological analysis. We also place special emphasis on HLA alleles prevalent in Asian populations, an important but underrepresented area in current neoantigen vaccine research.
To support translation, personalized mRNA-LNP vaccines can be produced within the GMP-compliant BioTReC Nucleic Acid Pilot Plant (BNAP). By combining scientific innovation with translational capability, we aim to improve the design and efficacy of personalized cancer vaccines and advance the most promising candidates toward clinical trials.
Advancing the translational research within Academia Sinica
The Biotechnology Research and Translation Program (BRTP) call for research projects with significant social and practical potential. The program supports biomedical research from preclinical development to proof-of-concept, seeking innovative solutions to address critical unmet medical needs.
Highlights
- Technology Transfer & Start-up
